Dr Richard D. Carvajal presents the final analysis of data from a phase II cross-over study in patients with metastatic melanoma of the eye during a press conference at the 2013 ASCO Annual Meeting in Chicago.  

The study found that selumetinib resulted in tumour shrinkage in half of all patients treated and a duration of disease control more than twice that achieved with temozolomide.

Visit ecancerNews to read more